Amneal Pharmaceuticals, Inc.

NasdaqGS:AMRX Stock Report

Market Cap: US$5.2b

Amneal Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:AMRX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
11 May 26SellUS$450,558Deborah AutorIndividual34,819US$12.94
31 Dec 25SellUS$86,005,134Dipan PatelIndividual6,924,729US$12.42
17 Nov 25SellUS$586,000Ted NarkIndividual50,000US$11.72
27 Aug 25SellUS$295,360John KielyIndividual32,000US$9.23
25 Aug 25SellUS$1,166,223Nikita ShahIndividual120,832US$9.66
20 Aug 25SellUS$977,809Andrew BoyerIndividual104,244US$9.38
15 Aug 25SellUS$4,663,070Anastasios KonidarisIndividual499,730US$9.43
14 Aug 25SellUS$666,037Nikita ShahIndividual71,694US$9.29
12 Aug 25SellUS$302,596Andrew BoyerIndividual33,436US$9.05
12 Aug 25SellUS$199,100Jason DalyIndividual22,000US$9.05
12 Aug 25SellUS$452,000Nikita ShahIndividual50,000US$9.04

Insider Trading Volume

Insider Buying: AMRX insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of AMRX?
Owner TypeNumber of SharesOwnership Percentage
State or Government79,3950.0249%
General Public13,889,2644.35%
Individual Insiders140,532,06744.1%
Institutions164,522,06651.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 78.56% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.2%
Tushar Patel
48,578,209US$787.5m0%no data
8.19%
Chintu Patel
26,141,773US$423.8m2.05%no data
7.69%
BlackRock, Inc.
24,519,192US$397.5m71.5%no data
7.1%
Chirag Patel
22,662,890US$367.4m2.42%no data
6.44%
Akram Mahesh
20,558,759US$333.3m0%no data
5.3%
Dipan Patel
16,904,263US$274.0m0%no data
3.86%
TPG Capital, L.P.
12,328,767US$199.8m0%0.9%
3.55%
Vanguard Portfolio Management, LLC
11,324,933US$183.6m0%0.01%
3.46%
Rubric Capital Management LP
11,037,589US$178.9m-10.5%1.92%
2.38%
Vanguard Capital Management, LLC
7,585,034US$123.0m0%no data
2.13%
State Street Global Advisors, Inc.
6,794,702US$110.1m65.3%no data
1.78%
Dimensional Fund Advisors LP
5,690,586US$92.2m1.45%0.01%
1.42%
Geode Capital Management, LLC
4,546,048US$73.7m14%no data
1.27%
Morgan Stanley
4,042,405US$65.5m-5.8%0.01%
1.15%
Neuberger Berman Investment Advisers LLC
3,682,284US$59.7m0.74%0.04%
0.96%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
3,068,183US$49.7m-0.14%0.01%
0.96%
Assenagon Asset Management S.A.
3,067,361US$49.7m-18.5%0.06%
0.96%
Invesco Capital Management LLC
3,047,768US$49.4m82.3%0.01%
0.89%
Nantahala Capital Management, LLC
2,844,108US$46.1m16.2%2.81%
0.8%
Allspring Global Investments, LLC
2,549,572US$41.3m72.3%0.06%
0.68%
Charles Schwab Investment Management, Inc.
2,184,161US$35.4m1.85%no data
0.62%
Goldman Sachs Asset Management, L.P.
1,963,152US$31.8m1.22%0.01%
0.61%
Acadian Asset Management LLC
1,931,894US$31.3m-4.42%0.03%
0.58%
Columbia Management Investment Advisers, LLC
1,865,201US$30.2m45.4%0.01%
0.54%
D. E. Shaw & Co., L.P.
1,719,954US$27.9m-35.4%0.02%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/20 21:50
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Amneal Pharmaceuticals, Inc. is covered by 20 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Glen SantangeloBarclays
Gary NachmanBMO Capital Markets Equity Research
David BuckB. Riley Securities, Inc.